1. Whether “[t]he panel misapprehended the intrinsic evidence to find that the specification ‘make[s] clear’ that a redundant construction is correct.”
2. Whether “the panel’s decision is contrary to at least the following decisions or precedents of this Court: Merck & Co. v. Teva Pharms. USA, Inc., 395 F.3d 1364 (Fed. Cir. 2005) and Apple, Inc. v. Ameranth, Inc., 842 F.3d 1229, 1237 (Fed. Cir. 2016), VLSI Tech. LLC v. Intel Corp., 53 F.4th 646 (Fed. Cir. 2022), and Phillips v. AWH Corp., 415 F.3d 1303, 1314 (Fed. Cir. 2005).”
